2. Search Result
Search Result
Results for "

retinopathy.

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

2

Biochemical Assay Reagents

3

Peptides

2

Inhibitory Antibodies

6

Natural
Products

1

Recombinant Proteins

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P4253A
    Arginyl-Glutamine TFA

    		VEGFR Cardiovascular Disease
    Arginyl-Glutamine TFA is a dipeptide that can decrease VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy .
    Arginyl-Glutamine TFA
  • HY-149325
    RPE65-IN-1

    		Others Others
    RPE65-IN-1(Compound 16e) is a potent RPE65 inhibitor, with an IC50 value of 0.29 μM. which can be used in retinopathy-related research .
    RPE65-IN-1
  • HY-115821
    Ascorutin

    Rutascorbin

    		 Others Metabolic Disease
    Ascorutin (Rutascorbin), a combination of ascorbic acid and rutoside, is utilized in the treatment of diabetic retinopathy.
    Ascorutin
  • HY-129685
    M79175

    		Aldose Reductase Metabolic Disease
    M79175 is an aldose reductase inhibitor that can be used in the study of early diabetic retinopathy .
    M79175
  • HY-P4253
    Arginyl-Glutamine

    		VEGFR Cardiovascular Disease
    Arginyl-Glutamine is a dipeptide that can decrease VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy .
    Arginyl-Glutamine
  • HY-P991429
    THR-317

    		VEGFR Metabolic Disease
    THR-317 is a human monoclonal antibody (mAb) targeting PLGF. THR-317 can be used in Diabetic retinopathy research .
    THR-317
  • HY-131528
    Tenilsetam

    CAS 997

    		 TNF Receptor Neurological Disease Metabolic Disease
    Tenilsetam (CAS 997) is an antidementia compound. Tenilsetam is an advanced glycation end product (AGE) inhibitor. Tenilsetam inhibits early retinopathy in experimental diabetes rats .
    Tenilsetam
  • HY-P991385
    UBX2050

    		Tie Neurological Disease Metabolic Disease
    UBX2050 is a human monoclonal antibody (mAb) targeting TIE2. UBX2050 can be used in Age-related macular degeneration, Diabetic macular oedema and Diabetic retinopathy research .
    UBX2050
  • HY-111603S
    Dobesilate-d6 calcium

    		Isotope-Labeled Compounds Apoptosis Others
    Dobesilate-d6 (calcium) is deuterium labeled Calcium dobesilate. Calcium dobesilate, a vasoprotective, is widely used in chronic venous disease, diabetic retinopathy and the symptoms of haemorrhoidal attack in many countries.
    Dobesilate-d6 calcium
  • HY-150052
    Plasma kallikrein-IN-3

    		Kallikrein Cardiovascular Disease Metabolic Disease
    Plasma kallikrein-IN-3 is a plasma kallikrein inhibitor (IC50: 0.15 μM). Plasma kallikrein-IN-3 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research .
    Plasma kallikrein-IN-3
  • HY-176164
    ALR2-IN-6

    		Aldose Reductase Neurological Disease Metabolic Disease
    ALR2-IN-6 (compound 9) is a potent and competitive ALR2 inhibitor with a Ki of 0.064 μM. ALR2-IN-6 can be used in the study of neuropathy, retinopathy, and nephropathy .
    ALR2-IN-6
  • HY-111603R
    Calcium dobesilate (Standard)

    		Reference Standards Apoptosis Others
    Calcium dobesilate (Standard) is the analytical standard of Calcium dobesilate. This product is intended for research and analytical applications. Calcium dobesilate, a vasoprotective, is widely used in chronic venous disease, diabetic retinopathy and the symptoms of haemorrhoidal attack in many countries.
    Calcium dobesilate (Standard)
  • HY-153464
    CXCR4-IN-1

    		CXCR Infection Cardiovascular Disease Inflammation/Immunology Cancer
    CXCR4-IN-1 (Example C5) is a CXCR4 inhibitor (IC50: 20 nM). CXCR4-IN-1 can be used for research of cancer, HIV, diabetic retinopathy, inflammation, etc .
    CXCR4-IN-1
  • HY-143476
    Plasma kallikrein-IN-2

    		Kallikrein Cardiovascular Disease Metabolic Disease
    Plasma kallikrein-IN-2 (Compound 198) is a potent plasma kallikrein (PKal) inhibitor with an IC50 of 0.1 nM. Plasma kallikrein-IN-2 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research .
    Plasma kallikrein-IN-2
  • HY-116301
    CAY10502

    		Phospholipase Inflammation/Immunology
    CAY10502 is a potent, calcium-dependent cytosolic phospholipase A2 α (cPLA2α) inhibitor with an IC50 of 4.3 nM for isolated enzyme. CAY10502 can be used in the research of retinopathy and inflammatory diseases .
    CAY10502
  • HY-122963
    Danshenol B

    		Adenosine Receptor Metabolic Disease
    Danshenol B is a diterpenoid. Danshenol B has strong aldose reductase (AR) inhibitory activity with IC50 value of 0.042μM. Danshenol B can be used for the research of diabetic related complication resulted by metabolic abnormality, such as cataracts, retinopathy, neuropathy, and nephropathy .
    Danshenol B
  • HY-139170
    CAY10746

    		ROCK Metabolic Disease
    CAY10746 is a selective Rho kinase (ROCK) inhibitor. CAY10746 has inhibitory activity for ROCK I, ROCK II with IC50 values of 0.014 μM and 0.003 μM, respectively. CAY10746 can be used for the research of diabetic retinopathy (DR) .
    CAY10746
  • HY-W715538
    Rhetsinine

    		Aldose Reductase Metabolic Disease
    Rhetsinine is an aldose reductase inhibitor isolated from Evodia rutaecarpa, exhibiting an IC50 value of 24.1 μM. At a concentration of 100 μM, rhetsinine significantly inhibits sorbitol accumulation by 79.3%. This compound shows potential for research in diabetic complications, including diabetic neuropathy and retinopathy .
    Rhetsinine
  • HY-150069
    UBX1325

    		Bcl-2 Family Apoptosis Metabolic Disease
    UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR) .
    UBX1325
  • HY-119112A
    LY 379196

    		PKC Neurological Disease
    LY 379196 is a PKC-β inhibitor (IC50: 50 nM and 30 nM for PKC βI and βII respectively). LY 379196 inhibits the VEGF, IGF-1 and bFGF-induced proliferation of bovine retinal microvascular endothelial cells (BREC). LY 379196 is an antiproliferatory agentfor proliferative retinopathy .
    LY 379196
  • HY-N11286
    Tridocosahexaenoylglycerol

    TG-DHA; Meganol D

    		 Others Neurological Disease Metabolic Disease Inflammation/Immunology
    Tridocosahexaenoylglycerol (TG-DHA) is an orally active dietary supplement that improves autoimmune encephalomyelitis in mice. Tridocosahexaenoylglycerol shows beneficial effects on neurodegenerative diseases and also improves macular function in diabetic retinopathy. Tridocosahexaenoylglycerol can be used for research on neurological diseases, inflammatory immune diseases, and metabolic diseases .
    Tridocosahexaenoylglycerol
  • HY-N0794
    Proanthocyanidins
    3 Publications Verification

    		 Bacterial Fungal Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Proanthocyanidin (Procyanidin) are a class of polyphenolic that are widely distributed in higher plants, consisted of an electrophilic flavanyl unit. Proanthocyanidin can be used as antioxidant and anti-cancers agent. Proanthocyanidin also exhibit anti-inflammatory, cardioprotective, antibacterial and antifungal properties, which can be used in the treatment of chronic venous insufficiency, capillary fragility, sunburn and retinopathy. .
    Proanthocyanidins
  • HY-Y0669S
    Pipecolic acid-d9

    		Isotope-Labeled Compounds Endogenous Metabolite Ferroptosis YAP Glutathione Peroxidase Infection
    Pipecolic acid-d9 is the deuterium labeled Pipecolic acid. Pipecolic acid is a metabolite of lysine and an important precursor for many useful microbial secondary metabolites. Pipecolic acid slows ferroptosis in diabetic retinopathy by inhibiting the YAP-GPX4 signaling pathway. In addition, Pipecolic acid can be used as a diagnostic marker for pyridoxine-dependent epilepsy .
    Pipecolic acid-d9
  • HY-175331
    ALR2-IN-7

    		Aldose Reductase Metabolic Disease Cancer
    ALR2-IN-7 (Compound 5a) is a highly potent and selective aldose reductase (ALR2/AKR1B1) inhibitor (Ki=8.71 nM). ALR2-IN-7 is promising for research of diabetic complications (e.g., retinopathy, nephropathy) and cancers .
    ALR2-IN-7
  • HY-Y0669R
    Pipecolic acid (Standard)

    		Reference Standards Endogenous Metabolite YAP Glutathione Peroxidase Ferroptosis Neurological Disease Metabolic Disease Inflammation/Immunology
    Pipecolic acid (Standard) is the analytical standard of Pipecolic acid. This product is intended for research and analytical applications. Pipecolic acid is a metabolite of lysine and an important precursor for many useful microbial secondary metabolites. Pipecolic acid slows ferroptosis in diabetic retinopathy by inhibiting the YAP-GPX4 signaling pathway. In addition, Pipecolic acid can be used as a diagnostic marker for pyridoxine-dependent epilepsy .
    Pipecolic acid (Standard)
  • HY-Y0669
    Pipecolic acid
    3 Publications Verification

    		 Endogenous Metabolite YAP Glutathione Peroxidase Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease Inflammation/Immunology
    Pipecolic acid is a metabolite of lysine and an immunomodulator, which can induce systemic acquired resistance (SAR) in plants. Pipecolic acid inhibits ferroptosis in diabetic retinopathy through the YAP-GPX4 signaling pathway. Pipecolic acid can induce apoptosis in neuronal cells. In addition, Pipecolic acid can be used as a diagnostic marker for pyridoxin-dependent epilepsy .
    Pipecolic acid
  • HY-N11286R
    Tridocosahexaenoylglycerol (Standard)

    TG-DHA (Standard); Meganol D (Standard)

    		 Reference Standards Others Neurological Disease Metabolic Disease Inflammation/Immunology
    Tridocosahexaenoylglycerol (Standard) is the analytical standard of Tridocosahexaenoylglycerol. This product is intended for research and analytical applications. Tridocosahexaenoylglycerol (TG-DHA) is an orally active dietary supplement that improves autoimmune encephalomyelitis in mice. Tridocosahexaenoylglycerol shows beneficial effects on neurodegenerative diseases and also improves macular function in diabetic retinopathy. Tridocosahexaenoylglycerol can be used for research on neurological diseases, inflammatory immune diseases, and metabolic diseases .
    Tridocosahexaenoylglycerol (Standard)
  • HY-111603
    Calcium dobesilate
    1 Publications Verification

    		 Apoptosis Metabolic Disease Inflammation/Immunology
    Calcium dobesilate is a vascular protector with oral activity that can clear hydroxyl free radicals, with an IC50 of 1.1 pM. Calcium dobesilate has antioxidant activity and helps to reduce oxidative stress and inflammation in the retinas of diabetic mice. Calcium dobesilate can be used to study chronic venous diseases, diabetic retinopathy, and the occurrence of hemorrhoids, among other conditions .
    Calcium dobesilate
  • HY-125639
    (rac)-AR-13503

    (rac)-AR-13324 M1 metabolite

    		 PKC ROCK Cardiovascular Disease
    (rac)-AR-13503 ((rac)-AR-13324 M1 metabolite) is the isoform of AR-13503 (HY-12798C). AR-13503 a ROCK/PKC inhibitor, inhibiting angiogenesis and enhancing retinal pigment epithelium (RPE) permeability. AR-13503 also inhibits the formation of aberrant neovascularization (NV) in oxygen-induced retinopathy (OIR) model in mice .
    (rac)-AR-13503
  • HY-143721
    SSAO inhibitor-2

    		Monoamine Oxidase Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    SSAO inhibitor-2 (Compound 1) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC50s of <10 nM, and 10-100 μM for human SSAO and MAO-A, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc .
    SSAO inhibitor-2
  • HY-145604
    Vicasinabin

    RG7774

    		 Cannabinoid Receptor Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Vicasinabin (RG7774) is an orally active, selective, and full CB2R agonist, with EC50 values of 2.81 nM and 2.60 nM for human CB2R and mouse CB2R, respectively. Vicasinabin inhibits inflammation, reduces leukocyte adhesion and decreases vascular permeability by selectively activating CB2R. Vicasinabin can be used in the researches for diabetic retinopathy, uveitis and laser-induced choroidal neovascularization .
    Vicasinabin
  • HY-143723
    SSAO inhibitor-3

    		Monoamine Oxidase Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    SSAO inhibitor-3 (Compound 2) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC50s of <10 nM, and 0.1-10 μM for human SSAO and AOC1, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc .
    SSAO inhibitor-3
  • HY-W031727
    Hydroxychloroquine
    Maximum Cited Publications
    72 Publications Verification

    		 Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy Infection Cancer
    Hydroxychloroquine (HCQ) is a synthetic oral antimalarial drug that can be used in the study of malaria and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Hydroxychloroquine is a potent autophagic flux inhibitor with antiviral activity (such as SARS-CoV-2 virus) that inhibits Toll-like receptor 7/9 (TLR7/9) signaling .
    Hydroxychloroquine
  • HY-W031727R
    Hydroxychloroquine (Standard)

    		Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy Infection Cancer
    Hydroxychloroquine (HCQ) is a synthetic oral antimalarial drug that can be used in the study of malaria and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Hydroxychloroquine is a potent autophagic flux inhibitor with antiviral activity (such as SARS-CoV-2 virus) that inhibits Toll-like receptor 7/9 (TLR7/9) signaling .
    Hydroxychloroquine (Standard)
  • HY-117133
    Nesvategrast

    SF0166

    		 Integrin Metabolic Disease
    Nesvategrast (SF0166) is a potent and selective αvβ3 antagonist with IC50 values of 0.6 nM, 8 nM, and 13 nM for αvβ3, αvβ6, and αvβ8, respectively. Nesvategrast inhibits cellular adhesion to vitronectin across human, rat, rabbit, and dog cell lines with IC50 values of 7.6 pM to 76 nM. Nesvategrast decreases neovascularization in the oxygen-induced retinopathy mouse model .
    Nesvategrast
  • HY-28099
    VEC6

    NSC 11435

    		 Endogenous Metabolite Cancer
    VEC6 (NSC 11435) is an inhibitor of VEZF1–DNA interaction and has the activity to recapitulate RhoB loss in ischemic retinopathy. VEC6 reduces pathological angiogenesis and promotes lymphangiogenesis. VEC6 plays a unique role in angiogenesis and lymphangiogenesis by regulating the expression of different sets of genes in endothelial cells. VEC6 has an inhibitory effect on VEZF1-mediated transcriptional activity, thereby affecting the proliferation and sprouting of endothelial cells .
    VEC6
  • HY-B2163
    Astaxanthin
    10+ Cited Publications

    		 PPAR Reactive Oxygen Species (ROS) STAT NF-κB Apoptosis Cardiovascular Disease Metabolic Disease Cancer
    Astaxanthin, the red dietary carotenoid, is an orally effective and potent antioxidant. Astaxanthin inhibits NF-κB and down-regulates VEGF in blood glucose. Astaxanthin exerts anti-cancer cell proliferation, increases apoptosis, impairs migration and invasion by activating PPARγ and reducing the expression of STAT3. Astaxanthin also has neuroprotective and anti-inflammatory activity and can be used in studies of cancer, diabetic retinopathy, cardiovascular disease, and in the coloring of animal feed .
    Astaxanthin
  • HY-165537
    Siphonaxanthin

    		FGFR Apoptosis Bcl-2 Family Caspase TNF Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Siphonaxanthin is a keto-carotenoid with anti-angiogenic and anti-inflammatory activity, which is found in green algae. Siphonaxanthin upregulates the expression of death receptor 5 (DR5), induces cancer cell apoptosis, decreases the expression of Bcl-2, and activates caspase-3. Siphonaxanthin is also an inhibitor of FGFR-1. Siphonaxanthin inhibits the proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs), as well as the outgrowth of microvessels in the rat aortic ring. Siphonaxanthin is promising for research of diseases such as cancer, diabetic retinopathy, and rheumatoid arthritis .
    Siphonaxanthin
  • HY-175663
    EYE-002

    		RPE65 Metabolic Disease
    EYE-002 is a RPE65 inhibitor with an IC50 of 69 nM. EYE-002 promotes recovery of scotopic ERG a-/b-wave amplitudes. EYE-002 regulates the visual cycle in mice by reducing 11-cis-retinal (11cRAL) (HY-116711) synthesis and increasing all-trans-retinyl esters (atREs). EYE-002 exerts protective effects against photic retinal damage in mice. EYE-002 can be used for the study of visual cycle-associated retinopathies, such as Stargardt disease type 1 (STGD1) .
    EYE-002
  • HY-175664
    EYE-003

    		RPE65 Metabolic Disease
    EYE-003 is an orally active RPE65 inhibitor with an IC50 of 102 nM. EYE-003 regulates the visual cycle in mice by reducing 11-cis-retinal (11cRAL) (HY-116711) synthesis and increasing all-trans-retinyl esters (atREs). EYE-003 suppresses scotopic ERG b-wave amplitude and exerts protective effects against retinal degeneration in Abca4 ⁻/⁻ Rdh8 ⁻/⁻ mice (a STGD1 model) by reducing retinal autofluorescent puncta and preserving outer nuclear layer (ONL) thickness in a dose-dependent manner. EYE-003 can be used for the study of visual cycle-associated retinopathies, such as Stargardt disease type 1 (STGD1) .
    EYE-003
  • HY-P3318
    Boc-Phe-Leu-Phe-Leu-Phe

    L-BOC2

    		 Leukotriene Receptor Inflammation/Immunology
    Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a N-formyl peptide receptors (FPR) inhibitor. Boc-Phe-Leu-Phe-Leu-Phe abolishes the FMLP-induced release of peptide leukotrienes. Boc-Phe-Leu-Phe-Leu-Phe inhibits the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids mediated by proliferative diabetic retinopathy (PDR) vitreous and vascular endothelial growth factor (VEGF) respectively in a three-dimensional fibrin gel. Boc-Phe-Leu-Phe-Leu-Phe inhibits the anti-inflammatory and antifibrotic effects of Ac2-26 (HY-P1098). Boc-Phe-Leu-Phe-Leu-Phe can be used for the study of immunology .
    Boc-Phe-Leu-Phe-Leu-Phe

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: